These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 3774121)

  • 1. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis.
    Costall B; Domeney AM; Naylor RJ; Tattersall FD
    Neuropharmacology; 1986 Aug; 25(8):959-61. PubMed ID: 3774121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs.
    Costall B; Domeney AM; Naylor RJ; Tattersall FD
    Neuropharmacology; 1987 Sep; 26(9):1321-6. PubMed ID: 2890117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
    Sorbe B; Hallén C; Frankendal B
    Cancer Chemother Pharmacol; 1994; 33(4):298-302. PubMed ID: 8281622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
    Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
    J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The actions of fenfluramine and interaction with 5-HT3 receptor-antagonists to inhibit emesis in the ferret.
    Costall B; Naylor RJ; Tattersall FD
    J Pharm Pharmacol; 1990 Feb; 42(2):94-101. PubMed ID: 1972409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probable involvement of the 5-hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs.
    Yamakuni H; Sawai H; Maeda Y; Imazumi K; Sakuma H; Matsuo M; Mutoh S; Seki J
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1002-7. PubMed ID: 10688616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin-induced emesis in the Ferret: a new animal model.
    Florczyk AP; Schurig JE; Bradner WT
    Cancer Treat Rep; 1982 Jan; 66(1):187-9. PubMed ID: 7198011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
    Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Hansen O; Sörensen BT; Räisänen I; van Oosterom AT; de Bruijn KM
    Cancer; 1994 Jan; 73(2):445-54. PubMed ID: 8293412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
    Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism.
    Miner WD; Sanger GJ
    Br J Pharmacol; 1986 Jul; 88(3):497-9. PubMed ID: 3742146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.
    Tattersall FD; Rycroft W; Francis B; Pearce D; Merchant K; MacLeod AM; Ladduwahetty T; Keown L; Swain C; Baker R; Cascieri M; Ber E; Metzger J; MacIntyre DE; Hill RG; Hargreaves RJ
    Neuropharmacology; 1996; 35(8):1121-9. PubMed ID: 9121615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties.
    Gylys JA; Wright RN; Nicolosi WD; Buyniski JP; Crenshaw RR
    J Pharmacol Exp Ther; 1988 Mar; 244(3):830-7. PubMed ID: 2978041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetic action of 5-HT3 receptor antagonists: review of preclinical and clinical results with ICS 205-930.
    Gamse R
    Cancer Treat Rev; 1990 Sep; 17(2-3):301-5. PubMed ID: 2272046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus.
    Horikoshi K; Yokoyama T; Kishibayashi N; Ohmori K; Ishii A; Karasawa A
    Jpn J Pharmacol; 2001 Jan; 85(1):70-4. PubMed ID: 11243577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of cisplatin induced emesis in the dog.
    Gylys JA; Doran KM; Buyniski JP
    Res Commun Chem Pathol Pharmacol; 1979 Jan; 23(1):61-8. PubMed ID: 441517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting.
    Anderson H; Thatcher N; Howell A; Logan K; Sage T; de Bruijn KM
    Eur J Cancer; 1994; 30A(5):610-5. PubMed ID: 8080674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tropisetron (ICS 205-930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide-based treatments.
    Cefalo G; Rottoli L; Armiraglio A; Pagan MG
    Am J Pediatr Hematol Oncol; 1994 Aug; 16(3):242-5. PubMed ID: 8037343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.